IceCure Medical Ltd

NasdaqCM ICCM

IceCure Medical Ltd Free Cash Flow for the year ending December 31, 2023: USD -13.00 M

IceCure Medical Ltd Free Cash Flow is USD -13.00 M for the year ending December 31, 2023, a 14.37% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

IceCure Medical Ltd Free Cash Flow for the year ending December 31, 2022 was USD -15.18 M, a -15.57% change year over year.
IceCure Medical Ltd Free Cash Flow for the year ending December 31, 2021 was USD -13.14 M, a -232.12% change year over year.
IceCure Medical Ltd Free Cash Flow for the year ending December 31, 2020 was USD -3.96 M, a -114.50% change year over year.
IceCure Medical Ltd Free Cash Flow for the year ending December 31, 2019 was USD -1.84 M, a 41.04% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: ICCM

IceCure Medical Ltd

CEO	Mr. Eyal Shamir
IPO Date	Aug. 26, 2021
Location	Israel
Headquarters	7 Ha’Eshel Street
Employees	71
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Key trends

Past 5 years